SRS ACQUIOM

# 2025 M&A Deal Terms Study

An analysis of deal terms in private-target M&A transactions that closed between 2019–2024


Please direct inquiries to: dts@srsacquiom.com

©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

POWERED BY SRS ACQUIOM MARKETSTANDARD

# Comprehensive Suite of Solutions

SRS Acquiom delivers the smartest way to run a deal™ with solutions that reduce the administrative burden.




*Securities products and Payments services offered through Acquiom Financial LLC, an affiliate broker-dealer of SRS Acquiom Inc. and member FINRA/SIPC. Visit www.finra.org for information about FINRA membership. Acquiom Financial does not make recommendations, provide investment advice, or determine the suitability of any security for any particular person or entity.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# The smartest way to run a deal™

Since 2007, we have helped sophisticated deal parties reduce administrative drag, enabling them to focus on building great businesses and maximizing value.

**10%+**
of all U.S. M&A transactions served*

**9,800+**
deals engaged on to date

**$1.7T+**
aggregate deal value

**560K+**
shareholders represented in more than 140 countries

---

**$1T+**
in payments

**99%**
of shareholders are paid within 24 hours†

**850K+**
total shareholders paid to date

*Statistics contained herein are derived from publicly available sources.*
*† Consideration given to those who have completed a Letter of Transmittal (LoT).*

SRSACQUIOM



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# About this Study and the Data

*The 2025 M&A Deal Terms Study is powered by SRS Acquiom MarketStandard®, a tool to analyze our proprietary database of more than 4,500 private-target M&A deals with customizable searches best suited to your specific transaction.*

*SRS Acquiom continually updates our databases for reporting deal-term data for 2019 through 2024. Therefore, results for prior years' data that is included in prior-year studies may in some cases differ in immaterial amounts from the 2025 SRS Acquiom M&A Deal Term Study. This study includes the most comprehensive and updated data available for all years. Sample sizes are larger in more recent years as a result of our growth. Medians are presented in addition to averages to counterbalance the effect of outliers. Some charts do not sum to 100% due to rounding. Data is presented on a calendar-year basis and is tied to the deal-closing date.*

*To benefit study users comparing data from different sources, this study presents similar data and terms with similar formatting and structure to the Private Target Deal Points Study published by the Mergers & Acquisitions Committee of the American Bar Association's Business Law Section, available at: https://www.americanbar.org/groups/business_law/about/committees/mergers-and-acquisitions/deal-points/*

SRS ACQUIOM

- *This study analyzes more than 2,200 private-target acquisitions ($505 billion) that closed from 2019 through 2024.*
- *SRS Acquiom provided professional and financial services on these deals; the vast majority of these are not publicly reported.*
- *Representations and Warranties Insurance (RWI) was identified on approximately 42% of 2024 deals in this study, compared to 38% in 2023, 40% in 2022 and 44% in 2021; buyers do not always disclose the presence of a buy-side RWI policy, and "no RWI identified" data subsets in this study likely include a small number of deals with RWI policies.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Representative Deals

| | | | | | | |
|---|---|---|---|---|---|---|
| AIOLOS BIO acquired by GSK | CADRE acquired by Yieldstreet | edata investment by Warburg Pincus, Accel Partners | Dedrone acquired by AXON | EQUILEND acquired by WCAS | EyeBio acquired by MERCK | Harveys Supermarket, Winn-Dixie acquired by ALDI |
| HI-Bio investment by Biogen | Ironshore Pharmaceuticals acquired by Collegium Pharmaceutical | Jackpocket acquired by DraftKings | mariana oncology acquired by Novartis | POWER ENGINEERS acquired by WSP | Procare Solutions acquired by Roper Technologies | PROTEOLOGIX acquired by Johnson & Johnson |
| RIMKUS investment by HGGC | RYTEC acquired by NUCOR | SRS Distribution acquired by The Home Depot | surescripts investment by TPG | TEXGEN acquired by TotalEnergies | TickPick investment by Brighton Park Capital | TRANSACT acquired by Roper Technologies |



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Table of Contents

Page numbers link to data slides. To return to the Table of Contents, click the bottom right page number on any page.


**Key Findings** ..... **8**

**Financial Terms and Provisions** ..... **9**
Transaction Values and Buyer Types ..... 10
Transaction Structure and Sign/Close Timing ..... 11
Transaction Values as Multiples of Equity Capital Invested ..... 12
Investment Exit Timing ..... 13
Closing Consideration Trends ..... 14
Management Carveouts ..... 15
Treatment of Options ..... 18
Post-closing Purchase Price Adjustments ..... 19
Earnouts ..... 25

**Pervasive Qualifiers** ..... **30**
Definition of Material Adverse Effect ..... 31
Knowledge Standards ..... 34

**Seller's Representations, Warranties, and Covenants** ..... **35**
"No Undisclosed Liabilities" Representation ..... 36
"Compliance with Laws" Representation ..... 37
"10b-5" and "Full Disclosure" Representations ..... 38
"No Other Representations" and "Non-reliance" Clauses ..... 41
Privacy Representation ..... 43
Cybersecurity Representation ..... 44
Sexual Misconduct Representation ..... 45
Covenants ..... 46

**Closing Conditions** ..... **48**
Accuracy of Seller's Representations ..... 49
"Material Adverse Change" Condition ..... 51
"No Legal Proceedings" Condition ..... 52
Legal Opinions (Non-tax) from Seller's Counsel ..... 53
Appraisal Rights Condition ..... 54

**Indemnification** ..... **56**
General Survival of Seller's Representations and Warranties ..... 57
Stand-alone Indemnities ..... 58
"Sandbagging" ..... 59
"Materiality Scrape" ..... 60
Reductions Against Buyer's Indemnification Claims ..... 62
Survival/Time to Assert Claims ..... 63
Baskets ..... 68
Caps ..... 74
Deal Escrows ..... 80
General Indemnification Escrows/Holdbacks ..... 82
Sources of Recovery ..... 85
Post-closing Expense Fund Sizes ..... 86
Indemnification as Exclusive Remedy for Breach ..... 87
Definition of Fraud ..... 88

**Dispute Resolution** ..... **89**
Waivers ..... 90
Alternative Dispute Resolution ..... 91
Sell-side Attorney-client Privilege ..... 93

**Termination Fees** ..... **94**

**Correlations** ..... **96**

**Example Terms** ..... **100**

**Glossary** ..... **112**

**MarketStandard®** ..... **118**

**Contact Information and Additional Resources** ..... **119**


SRSACQUIOM



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Key Findings

1 of 2

## Valuations on the Rise

- 2024 saw a 3x increase in "jumbo" transaction values ($750 million or more in upfront value) year over year, with about 20% fewer deals that had $100 million or less in upfront value (Slide 10▶).
- The median return on investment for 2024 deals remained the same as 2023 at 2.5x, albeit with a lower average year over year, and down from a median of 4x in 2022 (Slide 12▶). The median exit timing for M&A targets continued to rise (Slide 13▶).
- The percentage of deals with a management carveout went down slightly to about 5% (Slide 15▶), but the sizes increased (Slide 16▶), indicating distressed deals remain a small part of the mix.

## Deal Structures Are Adapting

- 2024, like 2022, saw increased activity from financial buyers, including Private Equity, with strategic buyers remaining about as active as they were in 2023 (Slide 10▶).
- 2024 saw a modest yet steady increase in all-cash deals (including deals with management rollovers), especially in the second and third quarters (Slide 14▶).

## Working Capital Purchase Price Adjustments (PPAs) Remain Ubiquitous

- We continue to see PPAs on almost every private-target M&A transaction, over 90% (Slide 19▶), with continually more complex and customized PPA provisions such as metrics (Slide 19▶), excluding tax-related items, and creating a custom calculation schedule or worksheet (Slide 20▶).
- The median size of separate PPA escrows has now settled around 1% of transaction value with more than three quarters of deals with a PPA including such a special escrow (Slide 22▶).

NEW DATA POINT

*"New Data Point" buttons appear on all slides featuring new data points throughout the study*

KEY FINDING

*Click on the "Key Finding" button throughout the study to return to the Key Findings on pages 7 and 8.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Key Findings

2 of 2

## Earnouts See Seller-favorable Shifts

- Inclusion of earnouts remained slightly elevated from historical norms of about 1 in 5 non-Life Sciences private-target deals but down dramatically from the spike in 2023 (Slide 25►).
- While the median remained steady at 24 months, performance periods are shifting shorter, with none longer than four years for 2024 non-Life Sciences private-target deals. (Slide 26►).

## Buyer Due Diligence Prompting Special Escrows and Indemnification Shifts

- Use of special escrows (in addition to the general indemnification escrow) continues and over half of 2024 deals include two or more escrows (Slide 80►).
- The number of deals with no survival of seller's general representations and warranties (i.e., walk-away deals) increased notably in 2024 for both traditional indemnity deals as well as deals with RWI (Slide 57►), which resulted in a corresponding slight decrease in general indemnity escrows (Slide 80►).
- Survival periods for seller's representations and warranties also noted shifts, with a confounding 50% increase in deals with a period shorter than 12 months (Slide 63►).

## General Trends and Observations

- The 2024 M&A market witnessed notable seller-favorable shifts in deal terms such as earnout and indemnification provisions. Where buyers held their ground is also noteworthy, such as "No Undisclosed Liabilities" reps (Slide 36►).
- The presence of RWI on a deal can materially affect certain indemnification terms [e.g., sandbagging (Slide 59►), materiality scrapes (Slide 61►), and baskets (Slide 69►)]. Even deals without RWI are seeing similar shifts [e.g., survival (Slide 57►), certain seller reps (Slide 39► and Slide 42►), and use of special escrows (Slide 80►)].


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.




# Financial Terms and Provisions


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# Transaction Values* and Buyer Types

KEY FINDING

TRANSACTION VALUES




BUYER TYPES†




** The term "transaction values" includes escrowed amounts but does not include potential earnout consideration.*


*† Beginning with deals closed in 2022, SRS Acquiom now distinguishes between U.S. private buyers that are backed by private equity (e.g., portcos) and those that are independent.*




©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Transaction Structure and Sign/Close Timing

TRANSACTION STRUCTURE (2021–2024)




TIMING OF SIGNING AND CLOSING (2024)






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Transaction Values as Multiples of Equity Capital Invested*

KEY FINDING

2024 DEALS

| Return: | Average | Median |
|---|---|---|
| 2024 | 5.6x | 2.5x |
| 2023 | 6.3x | 2.5x |
| 2022 | 9.1x | 4.0x |
| 2021 | 8.5x | 5.2x |
| 2020 | 6.3x | 3.5x |
| 2019 | 7.0x | 3.4x |





** Provided by PitchBook and other databases.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Investment Exit Timing

KEY FINDING

SUBSET: 2024 DEALS




| | Years to exit from date of first investment* | | Equity financing rounds at exit | | Equity capital invested* | |
|---|---|---|---|---|---|---|
| | MEDIAN | AVERAGE | MEDIAN | AVERAGE | MEDIAN | AVERAGE |
| 2024 | 6.9 | 8.2 | 4.0 | 4.6 | $34M | $91M |
| 2023 | 6.7 | 7.3 | 3.0 | 4.0 | $28M | $58M |
| 2022 | 6.5 | 7.0 | 3.0 | 3.9 | $19M | $49M |
| 2021 | 7.1 | 7.4 | 4.0 | 4.0 | $21M | $54M |
| 2020 | 6.1 | 6.9 | 3.0 | 3.7 | $26M | $54M |
| 2019 | 6.0 | 7.0 | 3.0 | 3.7 | $27M | $44M |


** Provided by PitchBook and other databases.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Closing Consideration Trends

KEY FINDING

CONSIDERATION TYPE




** Beginning with deals closed in 2022, SRS Acquiom now tracks when a cash transaction includes a management-rollover component.*

*This data point is influenced by Transaction Value.*

*Visit SRS Acquiom MarketStandard® to learn more.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Management Carveouts*


## Frequency

KEY FINDING

DEALS INCLUDING A MANAGEMENT CARVEOUT




MANAGEMENT CARVEOUT FREQUENCY BY TRANSACTION VALUE




* *A "management carveout" in this study is a portion of deal proceeds guaranteed to seller's management when management would otherwise receive little or nothing for their equity ownership due to liquidation preferences. Transaction bonuses, which often differ materially from management carveouts in size and timing of adoption, are not included above.*




©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Management Carveouts

## Size

KEY FINDING

MEDIAN SIZE AS A PERCENTAGE OF TRANSACTION VALUE*





** Measures size of carveout only, disregarding consideration received by seller management for equity ownership (if any).*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Management Carveouts

## Frequency by Return on Equity Capital Invested

DEALS INCLUDING A MANAGEMENT CARVEOUT





** Equity capital data provided by PitchBook and other databases.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Treatment of Options


## Contribution, Acceleration, and Assumption

CONTRIBUTION AND ACCELERATION*




** Excludes deals where optionholders received no consideration.*

ASSUMPTION OF OPTIONS BY BUYER






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Post-closing Purchase Price Adjustments


KEY FINDING

Buyers had a contractual right to review the estimated PPA calculations at or near the time of closing in 14% of 2024 deals with a PPA.

ADJUSTMENT PROVISION INCLUDED




ADJUSTMENT METRICS*




** 98% of post-closing purchase price adjustments in 2024 deals were based on more than one metric.*
*† Does not include post-closing adjustments for transaction expenses.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Post-closing Purchase Price Adjustments


## Working Capital Excludes Tax-related Items and Accounting Methodology

KEY FINDING


See example terms on slide 101

Subset: 2024 deals with a PPA

ADJUSTMENT EXCLUDES TAX-RELATED ITEMS




SUBSET: DEALS WITH POST-CLOSING PURCHASE PRICE ADJUSTMENTS




** "Other" methodology most commonly used was GAAP as modified by the principles and changes set forth on a schedule.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 


# Post-closing Purchase Price Adjustments

## Thresholds and Caps

See example terms on slide 101

Subset: 2024 deals with post-closing purchase price adjustments in the consideration mechanics section of the acquisition agreement (as opposed to the indemnification section only)


ADJUSTMENT ONLY IF THRESHOLD EXCEEDED




** Generally, payment out-of-pocket from securityholders.*

Subset: 2023 deals with a PPA, all of which included some form of PPA cap

CAP ON BUYER-FAVORABLE PURCHASE PRICE ADJUSTMENT CLAIMS




*"Other" includes specified dollar amounts not expressly tied to another deal term, such as the PPA escrow amount or general liability cap. More than 75% of "Other" cap amounts were less than the amount of the general indemnification escrow. 51% of deals with an "Other" cap amount included a separate PPA escrow.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# Purchase Price Adjustments

## Separate Escrows

KEY FINDING

For 2024 deals without a separate PPA escrow, the source of payment for a buyer-favorable adjustment is the indemnity escrow 67% of the time.

PERCENTAGE OF DEALS WITH PPA ESCROW AND MEDIAN SIZES




*For 2024 deals with a PPA, 91% with RWI identified and 66% with no RWI identified included a separate escrow for the PPA, compared to 88% and 57%, respectively, for 2023 deals.*

*For more information, see the SRS Acquiom thought leadership:*

*2025 M&A Working Capital PPA Study*

*Working Capital Adjustment M&A Checklist and Guidelines*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Purchase Price Adjustments


## Sell-side Information Rights

NEW DATA POINT

See example terms on slide 101

Over 92% of PPA provisions either require the final calculations preparer, typically the buyer, to deliver additional details with the statement or allow the sellers to request additional information in connection with their review of the statement. The two dark blue bars on the left side of the graph indicate what preparers must include when initially providing the statement.

SUBSET: 2024 DEALS WITH A PPA






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Purchase Price Adjustments


## Buyer Review of Estimate and Who Prepares the Final Post-closing Adjustment

NEW DATA POINT

BUYER'S CONTRACTUAL RIGHT TO APPROVE PPA ESTIMATE CALCULATIONS




WHO PREPARES THE FINAL CALCULATIONS POST-CLOSING?






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Earnouts (Non-Life Sciences Deals*)


KEY FINDING

Of the 22% of 2024 non-Life Sciences deals with an earnout, 32% had a single earnout and 68% had multiple earnouts.

EARNOUT INCLUDED




EARNOUT METRICS†





** For a more detailed analysis of SRS Acquiom's Life Sciences deals, please see the 2023 SRS Acquiom Life Sciences M&A Study.*
*† Earnouts can include more than one metric such as a combination of revenue and earnings.*
*‡ Examples: unit sales, product launches, divestiture of assets.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# Earnouts (Non-Life Sciences Deals*)

KEY FINDING

MEDIAN EARNOUT POTENTIAL AS % OF CLOSING PAYMENT†




EARNOUT LENGTH‡ (2024 MEDIAN: 24 MONTHS)




** For a more detailed analysis of SRS Acquiom's Life Sciences deals, please see the 2023 SRS Acquiom Life Sciences M&A Study.*
*† Calculated as the sum of potential earnout payments over the amount paid at closing (including escrowed amounts).*
*‡ Measured by the date the latest earnout period ends.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Earnouts (Non-Life Sciences Deals*)

## Covenants and Diligence Standards

NEW DATA POINT

SUBSET: 2024 DEALS WITH EARNOUTS, EXCLUDING LIFE SCIENCES DEALS




** For a more detailed analysis of SRS Acquiom's life sciences deals, please see the 2023 SRS Acquiom Life Sciences M&A Study.*

† This is a noticeable decrease from 2023 deals, when a CRE standard was included on over 30% of earnouts.




©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Earnouts (Non-Life Sciences Deals*)

## Acceleration and Offsets

SUBSET: 2024 DEALS WITH EARNOUTS, EXCLUDING LIFE SCIENCES DEALS




*† Generally subject to exceptions, such as if the subsequent buyer assumes the earnout obligations.*

*For more information, see the SRS Acquiom white paper:*

*A Review of Earnouts in M&A Transactions*

**For a more detailed analysis of SRS Acquiom life science deals, please see the full study:*

*2023 SRS Acquiom Life Sciences M&A Study*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Earnouts (Non-Life Sciences Deals*)


## Additional Provisions

See example terms on slide 101

### "EARNOUT IS NOT A SECURITY" PROVISION INCLUDED




### DISCLAIMER OF FIDUCIARY RELATIONSHIP (2024 DEALS)




** For a more detailed analysis of SRS Acquiom's life sciences deals, please see the 2023 SRS Acquiom Life Sciences M&A Study.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Pervasive Qualifiers


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# Definition of Material Adverse Effect ("MAE")

## "Prospects" Included and Forward-looking Language


See example terms on slide 102

98% of 2024 deals with an MAE definition had forward-looking language.*
Subset: 2024 deals with an MAE definition that included forward-looking language.

FORWARD-LOOKING MAE DETAILS




USE OF "PROSPECTS"




** Includes deals where the MAE definition did not include forward-looking language, but forward-looking language was predominantly used in conjunction with the use of the defined term in the body of the agreement.*

*† Definitions in the "Other" category used a combination of "could" and "would" or some other forward-looking standard.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# Definition of Material Adverse Effect

## Carveouts


See example terms on slide 102

Subset: MAE definition has carveouts

DEALS WITH CARVEOUTS




CARVEOUT FREQUENCY (2024 DEALS)





©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# Definition of Material Adverse Effect

## Carveouts Qualified by Disproportionate Effect

See example terms on slide 103

Subset: 2024 deals with an MAE definition with carveouts

DISPROPORTIONATE EFFECT DETAILS




*This data point is influenced by Transaction Value.*


*Visit SRS Acquiom MarketStandard® to learn more.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# Knowledge Standards

See example terms on slide 103

KNOWLEDGE DEFINITION DETAILS (2024 DEALS)




SUBSET: CONSTRUCTIVE*




** 17% of 2024 deals include more than one constructive knowledge element, e.g., a due inquiry requirement as well as role-based deemed knowledge.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Seller's Representations, Warranties, and Covenants


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# “No Undisclosed Liabilities” Representation

KEY FINDING


See example terms on slide 103

97% of 2024 deals contain “no undisclosed liabilities” representation.

PARTY FAVORED BY DEFINITION




REPRESENTATION IS KNOWLEDGE-QUALIFIED






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# “Compliance with Laws” Representation

See example terms on slide 103

99% of 2024 deals included this representation.

“COMPLIANCE WITH LAWS” REPRESENTATION DETAILS, 2024




*This data point is influenced by Transaction Value.*


*Visit SRS Acquiom MarketStandard® to learn more.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# “10b–5” and “Full Disclosure” Representations

See example terms on slide 104

INCLUSION OF REPRESENTATIONS (2024 DEALS)




*For more information, see the SRS Acquiom study:*

*Best Practices in Due Diligence*

** Does not include representations that apply only to the shareholder information statement (and not the acquisition agreement).*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# “10b–5” and “Full Disclosure” Representations

## Influence of RWI

KEY FINDING

DEAL YEARS 2021–2024






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# “10b–5” and “Full Disclosure” Representations


## Knowledge Qualifiers

Subset: 2021–2024 deals

SUBSET: “10B–5” REP ONLY




SUBSET: BOTH “10B–5” AND “FULL DISCLOSURE” REPS






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# “No Other Representations” and “Non-Reliance” Clauses

See example terms on slide 104

INCLUSION OF REPRESENTATIONS AND FRAUD CARVEOUTS (2024 DEALS)*




* 33% of deals with both clauses included a fraud carveout: 27% included the carveout for both clauses; 4% included the carveout for "No Other Reps" only; and 2% included the carveout for "Non-reliance" only.

*This data point is influenced by Transaction Value.*

*Visit SRS Acquiom MarketStandard® to learn more.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# “No Other Representations” and “Non-Reliance” Clauses

## Influence of RWI

KEY FINDING

2021–2024 DEALS






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# Privacy Representation

See example terms on slide 105

INCLUSION OF PRIVACY REPRESENTATIONS (2023 DEALS)




INCLUSION OF PRIVACY REPRESENTATIONS (2024 DEALS)






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# Cybersecurity Representation

See example terms on slide 105

INCLUSION OF CYBERSECURITY REPRESENTATIONS (2023 DEALS)




INCLUSION OF CYBERSECURITY REPRESENTATIONS (2024 DEALS)






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Sexual Misconduct Representation


See example terms on slide 105

INCLUSION OF SEXUAL MISCONDUCT REPRESENTATION (2024 DEALS)*





Subset: Deals with a sexual misconduct representation.


COVERS SETTLEMENT AGREEMENTS




COVERS ALLEGATIONS




CORRECTIVE ACTION LANGUAGE





* 68% of 2023 deals included a sexual misconduct representation, of which 43% covered settlement agreements, 71% covered allegations, and 17% included corrective action language.


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# Covenants

## Seller's Duty to Notify Buyer of Pre-Closing Breaches*

BREACHES OF REPRESENTATIONS AND WARRANTIES (2024 DEALS)




BREACHES OF COVENANTS (2024 DEALS)





** Sample excludes "sign-and-close" deals.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Covenants

## No-Shop/No-Talk*

NO-SHOP/NO-TALK COVENANT INCLUSION† (2024 DEALS)




** Sample excludes "sign-and-close" deals.*
*† Fiduciary exception subset excludes stock-purchase deals.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Closing Conditions*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Accuracy of Seller's Representations


## Accuracy and Materiality

See example terms on slide 106

ACCURACY: TIMING




ACCURACY: MATERIALITY (2024 DEALS)






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Accuracy of Seller's Representations (Materiality)


See example terms on slide 107

Subset: Deals with materiality or MAE qualifiers in the "accuracy of representations" condition

MAE QUALIFIER WITH CAPITALIZATION REPRESENTATION CARVEOUT




MATERIALITY SCRAPE FREQUENCY*





** Deals with materiality or MAE qualifiers in the "accuracy of representations" condition*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# “Material Adverse Change” Condition (“MAC”)

See example terms on slide 107

MAC CONDITION DETAILS (2024 DEALS)




*This data point is influenced by Transaction Value and Target Industry.*


*Visit SRS Acquiom MarketStandard® to learn more.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# “No Legal Proceedings” Condition

See example terms on slide 108

SUBSET: 2023 DEALS




SUBSET: 2024 DEALS







©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Legal Opinions (Non-tax) from Seller's Counsel

OPINION REQUIRED AS A CONDITION TO CLOSING





** Includes opinions delivered pursuant to both stand-alone and "closing deliverables" conditions.*
*† Does not account for opinions that may have been required or delivered outside of the express terms of the agreement.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# Appraisal Rights Condition

Subset: Mergers

APPRAISAL RIGHTS CONDITION INCLUDED




DRAFTING DETAILS (2024 DEALS INCLUDING CONDITION)




** Includes deals without an express appraisal rights condition but with a condition specifying a minimum percentage of shareholder votes (on a fully diluted basis) approving the merger, effectively waiving appraisal rights.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Appraisal Rights Condition

## Thresholds

Subset: Mergers since 2021 with an appraisal rights condition

CONDITION THRESHOLD DETAILS






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Indemnification



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# General Survival of Sellers' Representations and Warranties

KEY FINDING

33% of 2024 deals were structured as "no survival."

INFLUENCE OF REPS AND WARRANTIES INSURANCE (2021–2024)






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Stand-alone Indemnities*

FREQUENCY: 2024 DEALS COMPARED TO THE THREE-YEAR AVERAGE (2022–2024)†




** Line items for which indemnification is expressly provided beyond the standard line-item indemnities for seller's breaches of (i) representations and warranties and (ii) covenants.*
*† Percentages in the chart are for 2024 deals.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# “Sandbagging”


KEY FINDING

See example terms on slide 108

YEAR-OVER-YEAR TREND




SANDBAGGING PROVISION, DEAL YEARS 2021–2024






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# “Materiality Scrape” Inclusion

See example terms on slide 108-109

SUBSET: 2023 DEALS




SUBSET: 2024 DEALS





©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# “Materiality Scrape”

## Influence of RWI

KEY FINDING

See example terms on slide 109

MATERIALITY SCRAPE INCLUDED AND DETAILS (2021–2024)






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Reductions Against Buyer's Indemnification Claims

PROVISION INCLUDED




** Includes agreements requiring the buyer to seek payments under applicable insurance policies.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# General Survival Period/Time to Assert Claims

KEY FINDING

See example terms on slide 110

SURVIVAL PERIOD (2024 MEDIAN: 12 MONTHS)




| | Average | Median |
|---|---|---|
| 2024 | 12.7 | 12 |
| 2023 | 13.5 | 12 |
| 2022 | 13.3 | 12 |
| 2021 | 13.6 | 12 |
| 2020 | 13.8 | 15 |




©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Survival/Time to Assert Claims

## Carveouts to General Survival Period*

CARVEOUT FREQUENCY: 2024 DEALS COMPARED TO THE THREE-YEAR AVERAGE (2022–2024)†




** Matters subject to carveouts survive longer than the general survival period.*
*† Percentages in the chart are for 2024 deals.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Second-level Survival


## “Fundamental” and Tax Representations

Subset: 2024 deals that include the specified carveout. Years below denote additional survival time after expiration of the general survival period.

GROUP OF “FUNDAMENTAL REPRESENTATIONS”*




TAX REPRESENTATIONS




** For example: due organization, due authority, capitalization, etc. (other than taxes, intellectual property and fraud).*




©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Survival/Time to Assert Claims

## Carveouts to General Survival Period

"FUNDAMENTAL" REPRESENTATIONS CARVED OUT FROM THE GENERAL SURVIVAL PERIOD (MERGERS ONLY)






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Second-level Survival


## IP Representations and Fraud

Subset: 2024 deals that include the specified carveout. Years below denote additional survival time after expiration of the general survival period.

### INTELLECTUAL PROPERTY REPRESENTATIONS




### FRAUD/INTENTIONAL MISREPRESENTATION






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Baskets

## Definitions

See example terms on slide 110

BASKET FREQUENCY




*For more information, see the SRS Acquiom checklist:*

*M&A Seller Checklist: Post-Close Drafting Considerations*




©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Baskets

## Influence of RWI

KEY FINDING

BASKET TYPE DISTRIBUTION, DEALS 2021–2024






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Baskets as a Percentage of Transaction Value

Subset: Deals with deductible and first-dollar baskets

BASKET SIZES






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Baskets

## General Coverage*

Subset: Deals with baskets

COVERAGE DETAILS




** Carveouts to general basket coverage are discussed on the next slide.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Baskets

## Carveouts

Subset: 2024 deals with baskets

CARVEOUT FREQUENCY: 2024 DEALS COMPARED TO THE THREE-YEAR AVERAGE (2022–2024)†




*† Percentages in the chart are for 2024 deals.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Baskets

## Eligible Claim Threshold

See example terms on slide 111

THRESHOLD INCLUDED, YEAR-OVER-YEAR




*This data point is influenced by Transaction Value.*

*Visit SRS Acquiom MarketStandard® to learn more.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Caps as a Percentage of Transaction Value*

## All Deals

For 2024, the average cap was 11.1%; the median was 10.0%. These figures represent all deals, including those in which the buyer has purchased an RWI policy (which generally results in a lower liability cap).

DETAILS, 2022–2024




| | Average | Median |
|---|---|---|
| 2024 | 11.1% | 10.0% |
| 2023 | 10.1% | 10.0% |
| 2022 | 13.0% | 10.0% |

** In 2024 deals with escrows/holdbacks, 55% of caps equaled the escrowed amount.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Caps as a Percentage of Transaction Value

## No RWI Identified

When deals in which the buyer has definitively purchased an RWI policy are eliminated from the data set, the average cap for the remaining deals in 2024 was 14.6%; the median was 10.0%. Note that buyers do not always disclose the presence of a buy-side RWI policy, so this sample set likely includes some deals with policies.

DETAILS, 2022–2024




| | Average | Median |
|---|---|---|
| 2024 | 14.6% | 10.0% |
| 2023 | 13.0% | 11.7% |
| 2022 | 15.5% | 10.0% |



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Caps as a Percentage of Transaction Value

## RWI Identified

When the data set includes only deals in which the buyer has definitively purchased an RWI policy, the average cap for the remaining deals in 2024 was 2.9%; the median was 0.3%. Note that buyers do not always disclose the presence of a buy-side RWI policy, so this sample set likely omits some deals with policies.

DETAILS, 2022–2024





| | Average | Median |
|---|---|---|
| 2024 | 2.9% | 0.35% |
| 2023 | 2.9% | 0.4% |
| 2022 | 5.7% | 0.5% |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Caps

## Carveouts

FREQUENCY: 2024 DEALS COMPARED TO THE THREE-YEAR AVERAGE (2022–2024)†




*† Percentages in the chart are for 2024 deals.*




©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Second-level Caps


## “Fundamental” and Tax Representations

Subset: 2024 deals that include the specified carveout. Percentages below denote the second-level cap as a percentage of transaction value in absolute terms (not above the general cap).

“FUNDAMENTAL” REPRESENTATIONS*




TAX REPRESENTATIONS




** For example: due organization, due authority, capitalization, etc. (other than taxes, intellectual property, and fraud).*
*† “Other” includes, for example, offsets against future earnouts above the general cap.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Second-level Caps


## IP Representations and Fraud

Subset: 2024 deals that include the specified carveout. Percentages below denote the second-level cap as a percentage of transaction value in absolute terms (not above the general cap).

INTELLECTUAL PROPERTY REPRESENTATIONS




FRAUD/INTENTIONAL MISREPRESENTATION*




** Measures liability for shareholders that did not participate in the fraud (liability for participating shareholders was typically unlimited).*
*† "Other" includes, for example, offsets against future earnouts above the general cap.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# Deal Escrows*: 2024 Deals

## Frequency by Category and Aggregate Medians/Averages

KEY FINDING

Subset: 2024 deals

PERCENTAGE OF ALL DEALS THAT INCLUDE AN ESCROW, BY CATEGORY




* Includes holdbacks

Subset: 2024 deals with an indemnification escrow

AGGREGATE SIZE OF ALL ESCROWS AS A PERCENTAGE OF TRANSACTION VALUE

| | Average | Median |
|---|---|---|
| All deals | 10.25% | 10.0% |
| No RWI Identified | 13.2% | 11.3% |
| RWI Identified | 4.1% | 2.1% |

Subset: 2024 deals with an indemnification escrow

SIZE OF GENERAL INDEMNIFICATION ESCROWS AS A PERCENTAGE OF TRANSACTION VALUE

| | Average | Median |
|---|---|---|
| All deals | 7.8% | 9.0% |
| No RWI Identified | 10.9% | 10.0% |
| RWI Identified | 1.4% | 0.35% |



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Deal Escrows*: 2023 Deals

## Frequency by Category and Aggregate Medians/Averages

Subset: 2023 deals

PERCENTAGE OF ALL DEALS THAT INCLUDE AN ESCROW, BY CATEGORY




* Includes holdbacks

Subset: 2023 deals with an indemnification escrow

AGGREGATE SIZE OF ALL ESCROWS AS A PERCENTAGE OF TRANSACTION VALUE

| | Average | Median |
|---|---|---|
| All deals | 11.1% | 10.0% |
| No RWI Identified | 14.1% | 12.5% |
| RWI Identified | 4.3% | 2.5% |

Subset: 2023 deals with an indemnification escrow

SIZE OF GENERAL INDEMNIFICATION ESCROWS AS A PERCENTAGE OF TRANSACTION VALUE


| | Average | Median |
|---|---|---|
| All deals | 8.1% | 9.4% |
| No RWI Identified | 10.8% | 10.0% |
| RWI Identified | 2.0% | 0.5% |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# General Indemnification Escrows/Holdbacks as a Percentage of Transaction Value (All Deals*)

* Implied subset: This data (and the data on the next two slides) does not include deals without a general escrow/holdback, which constituted approximately 41% of all deals in 2024. That is up from 33% on 2023 and 34% in 2022.

DETAILS, 2022–2024





| | Average | Median |
|---|---|---|
| 2024 | 8.0% | 10.0% |
| 2023 | 8.1% | 9.5% |
| 2022 | 8.7% | 10.0% |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# General Indemnification Escrows/Holdbacks as a Percentage of Transaction Value (No RWI Identified)

When deals in which the buyer has definitively purchased an RWI policy are eliminated from the data set, the average escrow/holdback for the remaining deals in 2024 was 10.9%; the median was 10.0%. Note that buyers do not always disclose the presence of a buy-side RWI policy, so this sample set likely includes some deals with policies.

DETAILS, 2022–2024





| | Average | Median |
|---|---|---|
| 2024 | 10.9% | 10.0% |
| 2023 | 10.7% | 10.0% |
| 2022 | 11.4% | 10.0% |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# General Indemnification Escrows/Holdbacks as a Percentage of Transaction Value (RWI Identified)

When the data set includes only deals in which the buyer has definitively purchased an RWI policy, the average escrow/holdback for these deals in 2024 was 1.4%; the median was 0.3%. Note that buyers do not always disclose the presence of a buy-side RWI policy, so this sample set likely omits some deals with policies.

DETAILS, 2022–2024




| | Average | Median |
|---|---|---|
| 2024 | 1.4% | 0.35% |
| 2023 | 2.0% | 0.5% |
| 2022 | 1.2% | 0.5% |



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Sources of Recovery

## Escrows, Holdbacks, Insurance, and Setoffs

NEW DATA POINT

SUBSET: DEALS WITH POST-CLOSING INDEMNIFICATION




** "Other" includes setoff rights against buyer equity issued as consideration and post-closing installment payments (other than earnouts) as well as the rare case when only a subset of the selling shareholders are providing indemnification (e.g., management team or principal investor).*

*For more information, see the SRS Acquiom white paper:*


*Stock Escrows: Structure Matters When Using Buyer Equity in M&A Transactions*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Post-closing Expense Fund Sizes

Subset: Deals with expense funds* (96% of all 2024 deals)

MEDIAN/AVERAGE SIZES BY PERCENTAGE OF TRANSACTION VALUE




AVERAGE EXPENSE FUND SIZES BY DOLLAR AMOUNT†

| | 2023 | 2024 |
|---|---|---|
| Deals without earnouts | $194,000 | $227,000 |
| Deals with earnouts | $332,000 | $337,000 |

*For more information, see the SRS Acquiom white paper:*

*M&A Expense Funds: Why Sellers Should Establish One, How Large It Should Be, and Other Considerations*

** Funds established at closing to fund post-closing expenses.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Indemnification as Exclusive Remedy for Breach


See example terms on slide 111

Subset: 2024 deals

INDEMNIFICATION AS EXCLUSIVE REMEDY




CARVEOUTS TO EXCLUSIVE REMEDY






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Definition of Fraud

For 2024 deals where fraud was carved out from the "indemnification as sole remedy" provision, the definition of fraud included one or more of the following:

2024 DEALS




** Acquisition agreement language either expressly specified the laws of Delaware or included the elements of actual fraud and intent to deceive in the contractual definition of fraud.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.




# Dispute Resolution



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Waivers

LEGAL REPRESENTATION CONFLICT WAIVER* INCLUDED




WAIVER OF JURY TRIAL INCLUDED (2019–2024 DEALS)





** A provision allowing seller's pre-closing counsel to represent the selling shareholders post-closing in matters relating to the acquisition.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Alternative Dispute Resolution ("ADR")*

ADR INCLUSION




TYPE OF ADR (SUBSET: GENERAL ADR INCLUDED, 2024)





** Sample includes ADR provisions that apply to all disputes arising out of the agreement and does not include ADR provisions limited to particular matters such as purchase price adjustments or earnouts.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Alternative Dispute Resolution


Subset: Deals with general ADR included

INSTITUTION/RULES GOVERNING ARBITRATION




** "Other" frequently includes the International Chamber of Commerce.*

WHO PAYS ARBITRATION EXPENSES? (2024 DEALS)






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Sell-side Attorney-client Privilege

See example terms on slide 111


## WHO OWNS?† (2024 DEALS)




* *31% of agreements for 2024 deals were silent.*


† *32% of 2023 deals were silent and another 4% expressly named Buyer; 26% named the Selling Shareholders, 26% named the Selling Shareholders and Shareholder Rep, and 12% named the Shareholder Rep.*

## WHO CONTROLS? ‡ (2024 DEALS)




‡ *41% of 2023 deals were silent and another 2% expressly named Buyer; 15% named the Selling Shareholders, 16% named the Selling Shareholders and Shareholder Rep, and 25% named the Shareholder Rep.*

## SAVINGS CLAUSE§




§ *16% of 2023 deals included a Savings Clause.*



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Termination Fees



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Termination Fees

FEE PAID BY... (2024 DEALS)




FEES PAID BY BUYER





©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# Correlations


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# Correlations

## Transaction Value and Multiples, by Buyer Type

TRANSACTION VALUE VS. BUYER TYPE (2024 DEALS)




MULTIPLE OF RETURN* VS. BUYER TYPE (2024 DEALS)




** Equity capital investment data provided by PitchBook and other databases.*


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.


# Correlations

## Transaction Value and Escrow Size

Data set: All deals closing in 2021–2024

TRANSACTION VALUE VS. ESCROW SIZE (DEALS OVER $800M ARE HIDDEN BUT FACTOR INTO TREND LINE)

Each point is a deal; linear fit line in teal






©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 


# Correlations

## Transaction Value and Escrow Size (Detail)

Data set: All deals closing in 2021–2024

TRANSACTION VALUE VS. ESCROW SIZE (DEALS OVER $200M ARE HIDDEN BUT FACTOR INTO TEAL TREND LINE)

Deals ≤ $50M: Each teal point is a deal; linear fit line in dark gray
Deals > $50M: Each orange point is a deal; linear fit line in teal





©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential.

# Example Terms

Example terms included in this study are provided as a reference only and may not be applicable to certain deals.


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Example Terms (1 of 11)

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **Post-closing Purchase Price Adjustments:** Working Capital Excludes Tax-related Items | **Tax Exclusion Example**<br>"Adjusted Working Capital" means (a) the sum of the Company's current assets, excluding any current or deferred tax assets, less (b) the sum of the Company's current liabilities, excluding any current or deferred tax liabilities, calculated in accordance with the Accounting Principles and the line items in the illustrative Net Working Capital calculation set forth on Exhibit 1. | Slide 20 ➤ |
| **Post-closing Purchase Price Adjustments:** Accounting Methodology | **Example Provision Establishing Accounting Methodology:**<br>The parties shall prepare the Closing Statement in accordance with the applicable definitions in this Agreement and with GAAP and, solely to the extent consistent with GAAP, in accordance with the Company's past practices (including the methodologies applied in the preparation of the Financial Statements); provided that if there is any inconsistency between GAAP and the definitions in this Agreement relating to the items to be set forth on the Closing Statement, the definitions shall control. | Slide 20 ➤ |
| **Post-closing Purchase Price Adjustments:** Thresholds and Caps | **Example Threshold and Cap Language:**<br>If the Final Working Capital Difference Amount is a negative number, the absolute value of which exceeds the Adjustment Threshold Amount, the Closing Merger Consideration shall be decreased by the amount the absolute value of the Final Working Capital Difference Amount exceeds the Adjustment Threshold Amount not to exceed the Purchase Price Adjustment Cap. | Slide 21 ➤ |

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **Post-closing Purchase Price Adjustments:** Sell-side Information Rights | **Supporting Information Delivered with Statement Example Clause**<br>...including any supporting information reasonably necessary for the Shareholder Representative to review such calculations.<br><br>**Cooperation and Access During Review Example Term**<br>Buyer will, and will cause the Company to, reasonably cooperate with the Shareholder Representative in the review of the Final Closing Statement and provide the Shareholder Representative and its representatives with reasonable access during normal business hours to the books, records (including work papers, schedules, memoranda, and other documents), supporting data, facilities, and employees of Buyer and all other information in connection with the review of the Final Closing Statement as is reasonably requested by the Shareholder Representative or any of its representatives. | Slide 23 ➤ |
| **Earnouts (Non-Life Sciences Deals):** Additional Provisions | **Example Provision Intended to Ensure Earnout Is Not Treated as a Security:**<br>The right of Seller to a portion of the Earnout Amount, if any, shall not be represented by a certificate or other instrument, shall not represent an ownership interest in Buyer or the Business and shall not entitle Seller to any rights common to any holder of any equity security of Buyer.<br><br>**Example Disclaimer of Fiduciary Relationship:**<br>Nothing in this Agreement creates a fiduciary duty on the part of Buyer to Seller in respect of the Earnout. | Slide 29 ➤ |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Example Terms (2 of 11)

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **Definition of Material Adverse Effect ("MAE"):** "Prospects" Included | **Example Term** "Material Adverse Effect" means any result, fact, change, circumstance, occurrence, event or effect that, individually or in the aggregate, has a material adverse effect on the condition (financial or otherwise), assets (including intangible assets), liabilities, businesses, prospects, capitalization, operations, or results of operations of the Seller, taken as a whole. | Slide 31 ➤ |
| **Definition of Material Adverse Effect ("MAE"):** Forward-looking Language | **Example Term:** "Material Adverse Effect" means any result, fact, change, circumstance, occurrence, event or effect that, individually or in the aggregate, has had, or could reasonably be expected to have, a material adverse effect on the condition (financial or otherwise), assets (including intangible assets), liabilities, businesses, prospects, capitalization, operations, or results of operations of the Company, taken as a whole. | Slide 31 ➤ |

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **Definition of Material Adverse Effect ("MAE"):** Carveouts | **Example Term:** … provided, however, Material Adverse Effect will not include the following, either alone or in combination, nor will any of the following be taken into account in determining whether there has been a Material Adverse Effect: (a) effects, changes, events, developments, circumstances or conditions that generally affect the industry in which the Company operates; (b) general business, financial or economic conditions; (c) national or international political or social conditions, including the engagement in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any actual or threatened military or terrorist attack; (d) changes or developments resulting or caused by natural disasters; (e) changes or developments resulting from any epidemic, pandemic, disease outbreak, or other public health emergency; (f) changes in GAAP or in the interpretation or enforcement thereof; or (g) effects, changes, events, developments, circumstances or conditions arising out of or attributable to any action required by this Agreement or any action taken (or omitted to be taken) with the written consent of or at the written request of the Buyer. | Slide 32 ➤ |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Example Terms (3 of 11)

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **Definition of Material Adverse Effect:** Carveouts Qualified by Disproportionate Effect | **Example Term:** … provided, however, Material Adverse Effect will not include the following, either alone or in combination, nor will any of the following be taken into account in determining whether there has been a Material Adverse Effect: (a)… (b)… … (g)…; provided, however, that the foregoing clauses (a) through (g) will not apply and may be taken into account if such effect, change, event, development or circumstance disproportionately adversely affects the Seller, taken as a whole, compared to other Persons that operate in the industry in which the Seller operates. | Slide 33 ➤ |
| **Knowledge Standards** | **Actual Knowledge** "Knowledge" means, with respect to (a) the Seller, the actual knowledge of the officers and directors of the Company, or (b) with respect to any other Party, …. **Constructive Knowledge** "Knowledge" means, with respect to (a) the Seller, the actual knowledge of the officers and directors of the Seller and the knowledge of which any such individual should have been aware, in their capacity as an officer or director of the Seller, after reasonable inquiry, or (b) with respect to any other Person, …. | Slide 34 ➤ |

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **"No Undisclosed Liabilities" Representation Examples** | **Buyer-favorable Formulation** The Seller has no liabilities of any type whatsoever except for: (a) liabilities reflected or reserved against in the Balance Sheet; (b) those Liabilities set forth in the Disclosure Schedule; and (c) current liabilities incurred in the ordinary course of business during the Interim Period. **Seller-favorable Formulation** The Seller has no liabilities of any type that are required to be disclosed in a balance sheet prepared in accordance with GAAP except for (a) liabilities reflected or reserved against in the Latest Balance Sheet; (b) those Liabilities set forth in the Disclosure Schedule; and (c) current liabilities incurred in the ordinary course of business during the Interim Period. | Slide 36 ➤ |
| **"Compliance with Laws" Representation** | **Example Representation** The Seller is, and has been, to Seller's knowledge, in compliance in all material respects, with all applicable Laws. | Slide 37 ➤ |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Example Terms (4 of 11)

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **"10b–5" and "Full Disclosure" Representations Examples** | **"10b–5" Representation**<br>No representation or warranty by the Seller in this Agreement and no statement contained herein, in the Disclosure Schedules, or any certificate or other document furnished or to be furnished to Buyer, pursuant to this Agreement, contains any untrue statement of a material fact, or omits to state a material fact necessary to make the statements contained therein, in light of the circumstances under which they are made, not misleading in any material respect.<br><br>**"Full Disclosure" Representation**<br>The Seller has no Knowledge of any information or other fact that is, or reasonably likely to become, materially adverse to the condition (financial or otherwise), assets, business, capitalization, liabilities, operations, prospects, results of operations, or financial performance of the Company that has not been set forth in this Agreement or in the Disclosure Schedules. | Slide 38 ➤ |

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **"No Other Representations" and "Non-reliance" Clause Examples** | **No Other Representations**<br>Buyer hereby expressly acknowledges that the Seller has not made and is not making any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except for the representations and warranties contained in this Article (as modified by the Disclosure Schedule).<br><br>**Non-Reliance**<br>Buyer hereby expressly acknowledges that it is not relying and has not relied on any representations or warranties whatsoever regarding the subject matter of this Agreement, express or implied, except for the representations and warranties contained in this Article (as modified by the Disclosure Schedule). | Slide 41 ➤ |
| **"No Other Representations" and "Non-reliance" Clause Fraud Carveout** | **Example Fraud Carveout Clause**<br>…except that nothing in this Agreement will limit or exclude any liability of a Party for Fraud. | Slide 41 ➤ |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Example Terms (5 of 11)

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **Privacy Representation Example** | **Example Privacy Representation**<br>The Seller has complied in all material respects with all applicable Privacy Laws and has in place adequate written policies relating to privacy, data protection, and the collection and use of Personal Data and other sensitive data collected, used, or held for use by the Seller, to comply with its obligations under all applicable Privacy Laws (collectively the "Seller Privacy Policies"). The Seller has not received any written notice, order, inquiry, investigation, complaint, or other communication alleging non-compliance with any Privacy Laws or Seller Privacy Policies. To the Seller's Knowledge, there has been no material loss, theft, misuse of, or unauthorized access to, or acquisition, use, modification or disclosure of, any Personal Information processed, collected, stored, transferred or otherwise used by or on behalf of the Seller. The Transaction will not result in any material liabilities in connection with any applicable Privacy Laws. | Slide 43 ➤ |
| **Cybersecurity Representation** | **Example Cybersecurity Representation**<br>Seller's information technology equipment, systems and processes, whether owned, used or held for use by Seller, are reasonably sufficient for the needs of Seller's business. No unauthorized access, use or intrusion, breach of security, material failure or diminished performance, or other adverse event relating to Seller's information technology infrastructure has caused or would reasonably be expected to cause any substantial disruption to Seller's business or any material loss or harm to Seller or its directors, officers, employees, contractors, property or other assets. | Slide 44 ➤ |

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **Sexual Misconduct Representation** | **Example Sexual Harassment and Misconduct Representation (aka #metoo Rep or Weinstein clause)**<br>The Seller is not a party to any settlement agreement relating to allegations of sexual harassment, discrimination or other misconduct involving Seller or any current or former director, officer, employee, or contractor of Seller or its Affiliates. To Seller's knowledge, no allegations of or investigations into sexual harassment, discrimination or other misconduct have been made against Seller or any current or former director, officer, employee, or contractor of Seller or its Affiliates.<br><br>**Example Corrective Action Language**<br>Seller promptly reviews and investigates all allegations of sexual harassment, discrimination, or other misconduct and takes timely corrective action that is reasonably calculated to prevent further instances of sexual harassment, discrimination or other misconduct. | Slide 45➤ |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Example Terms (6 of 11)

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **Accuracy of Seller's Representations (Timing):** When Must They Be Accurate? | **At Signing Only**<br>Each of the representations and warranties set forth in this Article will be true and correct in all material respects as of the date hereof, or for representations and warranties that refer specifically to an earlier date, will have been true and correct in all material respects as of such specified date.<br><br>**At Closing Only**<br>Each of the representations and warranties set forth in this Article will be true and correct in all material respects as of the Closing Date as though made on and as of the Closing Date, or for representations and warranties that refer specifically to an earlier date, will have been true and correct in all material respects as of such specified date.<br><br>**At Signing and Closing**<br>Each of the representations and warranties set forth in this Article will be true and correct in all material respects as of the date hereof and as of the Closing Date as though made on and as of the Closing Date, or for representations and warranties that refer specifically to an earlier date, will have been true and correct in all material respects as of such specified date. | Slide 49 ➤ |

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **Accuracy of Seller's Representations (Timing):** How Accurate Must They Be? | **Accurate "in all respects"**<br>Each of the representations and warranties set forth in this Article will be true and correct in all respects as of the date hereof and as of the Closing Date as though made on and as of the Closing Date, or for representations and warranties that refer specifically to an earlier date, will have been true and correct in all respects as of such specified date.<br><br>**Accurate "in all material respects"**<br>Each of the representations and warranties set forth in this Article will be true and correct in all material respects as of the date hereof and as of the Closing Date as though made on and as of the Closing Date, or for representations and warranties that refer specifically to an earlier date, will have been true and correct in all material respects as of such specified date.<br><br>**MAE qualification**<br>Each of the representations and warranties set forth in this Article will be true and correct in all respects as of the date hereof and as of the Closing Date as though made on and as of the Closing Date (or for representations and warranties that refer specifically to an earlier date, will have been true and correct in all respects as of such specified date), except where failure to be so true and correct do not and could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. | Slide 49 ➤ |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Example Terms (7 of 11)

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **Accuracy of Seller's Representations (Materiality):** MAE Qualifier with Capitalization Representation Carveout | **Example Capitalization Carveout**<br>Each of the Seller's representations and warranties set forth in this Article, other than Section 3.2 (the Capitalization Representations), will be true and correct in all respects as of the date hereof and as of the Closing Date as though made on and as of the Closing Date (or for representations and warranties that refer specifically to an earlier date, will have been true and correct in all respects as of such specified date), except where failure to be so true and correct do not and could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect; and each of the Capitalization Representations will be true and correct in all respects as of the Closing Date as though made on and as of the Closing Date. | Slide 50 ➤ |
| **Accuracy of Seller's Representations (Materiality):** Materiality Scrape | **Example Materiality Scrape**<br>Each of the representations and warranties set forth in this Article will be true and correct in all material respects as of the date hereof and as of the Closing Date as though made on and as of the Closing Date, or for representations and warranties that refer specifically to an earlier date, will have been true and correct in all material respects as of such specified date; provided, however, that for purposes of determining the accuracy of such representations and warranties, all qualifications limiting the scope of such representations and warranties, including by the words "Material Adverse Effect," "in all material respects," "in any material respect," "material," or "materiality," will be disregarded. | Slide 50 ➤ |

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **"Material Adverse Change" Condition ("MAC")** | **"Stand-alone" MAC**<br>No Company Material Adverse Effect will have occurred between the date of this Agreement and the Closing Date that is continuing.<br><br>**"Back-door" MAC**<br>The acquisition agreement includes an "Absence of Changes" representation and a bring-down condition regarding the accuracy of the Seller's representations and warranties at Closing, which collectively create the "Back-door" MAE condition, as per below:<br><br>*Absence of Changes. (i) Since the Balance Sheet Date, there has not been, except as set forth in the Disclosure Schedules, any Seller Material Adverse Change.*<br><br>*Conditions to Obligations of the Buyer. … (a) The representations and warranties set forth in Article III shall be true and correct in all respects when made and at the Closing Date as if made on the Closing Date, except, where the failure of any such representations or warranties to be true and correct do not and could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.* | Slide 51➤ |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Example Terms (8 of 11)

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **"No Legal Proceedings" Condition** | **Example Formulation**<br>There will not be any (a) [threatened or] pending legal action, suit, or similar legal proceeding brought by any Person or Government Authority with respect to the Transaction, or (b) any injunction, restraining order, or Law, whether temporary, preliminary, or permanent, issued by any Government Authority, directing the Transaction to not be consummated. | Slide 52 ➤ |
| **"Sandbagging"** | **Pro-sandbagging**<br>The right to indemnification, reimbursement, or other remedies based upon any such representation or warranty will not be affected by any Knowledge acquired (or capable of being acquired) at any time, whether before or after the execution and delivery of this Agreement or the Closing Date, with respect to the accuracy or inaccuracy of such representation warranty…<br><br>**Anti-sandbagging**<br>No Party will be liable under this Article for any Losses arising from or relating to the inaccuracy of, breach of, non-performance of, or non-compliance with any representation, warranty, or obligation in this Agreement if the Party bringing a claim for such Losses had Knowledge of such inaccuracy, breach, non-performance, or non-compliance prior to the Closing. | Slide 59 ➤ |

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **"Materiality Scrape" Example Definitions** | **Materiality qualifications in representations and warranties disregarded for all indemnification purposes (determining breaches and calculating losses)**<br><br>Notwithstanding anything to the contrary in this Agreement, for purposes of the indemnification provisions in this Article, the determination of (a) whether any representation warranty or covenant has been breached and (b) the amount of any Losses will be made without giving effect to any "Material Adverse Effect" qualification or any materiality or similar qualification contained in the representations, warranties, covenants or agreements herein.<br><br>**Materiality qualifications in representations and warranties disregarded for calculation of losses only**<br><br>Notwithstanding anything to the contrary in this Agreement, for purposes of the indemnification provisions in this Article, the determination of the amount of any Losses will be made without giving effect to any "Material Adverse Effect" qualification or any materiality or similar qualification contained in the representations, warranties, covenants or agreements herein.<br><br>(Continued in next column) | Slide 60 ➤ |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Example Terms (9 of 11)

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **"Materiality Scrape" Example Definitions**<br>(continued) | **Materiality qualifications in representations and warranties disregarded for determining breaches only**<br><br>Notwithstanding anything to the contrary in this Agreement, for purposes of the indemnification provisions in this Article, the determination of whether any representation warranty or covenant has been breached and will be made without giving effect to any "Material Adverse Effect" qualification or any materiality or similar qualification contained in the representations, warranties, covenants, or agreements herein. | Slide 60 ➤ |

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **Reductions Against Buyer's Indemnification Claims** | **Reduction for insurance proceeds**<br>Payments by an Indemnifying Party pursuant hereto shall be limited to the amount of any liability or damage that remains after deducting therefrom any insurance proceeds and any indemnity, contribution, or other similar payment received or reasonably expected to be received by the Indemnified Party in respect of any such claim.<br><br>**Reduction for tax benefits**<br>Payments by an Indemnifying Party pursuant hereto for any Loss shall be reduced by an amount equal to any Tax benefit realized or reasonably expected to be realized as a result of such Loss by the Indemnified Party.<br><br>**Buyer required to mitigate losses**<br>Each Indemnified Party shall take, and cause its Affiliates to take, all reasonable steps to mitigate any Loss upon becoming aware of any event or circumstance that would be reasonably expected to, or does, give rise thereto, including incurring costs only to the minimum extent necessary to remedy the breach that gives rise to such Loss and using commercially reasonable efforts to recover under insurance policies or indemnity, contribution, or other similar agreements for any Losses. | Slide 62 ➤ |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Example Terms (10 of 11)

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **General Survival Period/Time to Assert Claims** | **Survival**<br>All representations, warranties, and covenants in this Agreement and the Disclosure Schedules and any other certificate or document delivered pursuant to this Agreement will survive the Closing for a period of 15 months.<br><br>**Time Limitations**<br>If the Closing occurs, Seller will have no liability (for indemnification or otherwise) with respect to any representation or warranty unless on or before the 15-month anniversary of the Closing, Buyer notifies Sellers of a Claim specifying the factual basis of such Claim in reasonable detail to the extent then known by Buyer. | Slide 63 ➤ |

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **Baskets:** Definitions | **Deductible**<br>With respect to indemnification by the Sellers for any Losses arising under this Article, the Sellers will not be liable unless and until the aggregate amount of all Losses for which the Sellers would be liable exceeds an amount equal to $[500,000] (the “Deductible”), in which case the Sellers will only be liable for such Losses in excess of the Deductible.<br><br>**First-dollar**<br>With respect to indemnification by the Sellers for any Losses arising under this Article, the Sellers will not be liable unless and until the aggregate amount of all Losses for which the Sellers would be liable exceeds an amount equal to $[500,000] (such amount, the "Sellers Basket"). If indemnification claims exceed the Sellers Basket, the Sellers will be liable for all indemnification claims properly asserted against them, including those claims comprising the Sellers Basket.<br><br>**Combination**<br>With respect to indemnification by the Sellers for any Losses arising under this Article, the Sellers will not be liable unless and until the aggregate amount of all Losses for which the Sellers would be liable exceeds an amount equal to $[1,000,000] (the "Threshold"), at which time Sellers will be liable only to the extent that such cumulative Losses exceed $[500,000] (the "Deductible").” | Slide 68 ➤ |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Example Terms (11 of 11)

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **Baskets:** Eligible Claim Threshold | **Claim Threshold Formulation**<br>No claim for Losses may be made for indemnification hereunder if the amount of such claim, or series of related claims, individually or in the aggregate, does not exceed $20,000 (the "De Minimis Amount"), it being understood that a claim for Losses that does not exceed the De Minimis Amount will not count toward satisfaction of the Deductible. | Slide 73 ➤ |
| **Indemnification as Exclusive Remedy for Breach** | **Example provision for Exclusive Remedy**<br>The parties acknowledge and agree that their sole and exclusive remedy with respect to any and all claims (other than claims arising from fraud) for any breach of any representation, warranty, covenant, agreement, or obligation set forth herein or otherwise relating to the subject matter of this Agreement, shall be pursuant to the indemnification provisions set forth herein. | Slide 87 ➤ |

| TOPIC | EXAMPLE TERMS | SEE DATA |
|---|---|---|
| **Sell-side Attorney-client Privilege** | **Example Savings Clause for Transfer of Sell-side Attorney-client Privilege to Selling Shareholders**<br>Buyer hereby agrees not to search for or use any Deal Communications existing on the Company's electronic backup systems, email archives or other books and records after the Closing, the existence of any Deal Communications in the Company's possession after the Closing shall not be deemed a waiver of the privilege related to such Deal Communications, and the parties agree to take all reasonable steps necessary to ensure such privilege shall survive the Closing.<br>See **Anatomy of the Target Company Privilege Provision in M&A Agreements** for additional example language. | Slide 93 ➤ |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Glossary


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Glossary (#– C)

| | |
|---|---|
| 10b-5 | Rule 10b-5 is an SEC rule that prohibits any act or omission resulting in fraud or intentional deceit (scienter) and relied upon by the injured party in connection with the purchase or sale of a security. A "10b-5 Representation" is a catch-all representation in the merger agreement modeled from the SEC rule but without the scienter or reliance requirement, expanding buyer's ability to claim breach of the agreement. |
| Adjusted Working Capital | A method of calculating working capital where certain items are expressly included or excluded from current assets or current liabilities such as deferred tax assets (e.g., loss carry forward) or contingent liabilities (e.g., pending litigation). |
| Appraisal Rights | Shareholders' statutory right under state law to seek judicial determination of the value of their shares when the target company is party to a merger. |
| Arbitration | A method of alternative dispute resolution whereby a dispute, with the consent of the parties, is submitted to a neutral person or group for a decision. Usually includes a full evidentiary hearing and presentations by attorneys for the parties. The merger agreement may provide that the arbitrator's decision be binding or non-binding. |
| Baskets (Indemnification) | A limitation on the Seller's indemnification of the Buyer by setting a deductible (i.e., the Seller is only responsible for losses above the deductible), threshold (i.e., the Seller is responsible for all losses only after such losses hit the threshold amount, also known as a "tipping basket" or a "first-dollar basket") or both with respect to aggregated claims. Baskets may also be set for individual claims. |
| Buy-side Representations And Warranties Insurance (RWI) | An insurance policy issued to the Buyer in an M&A transaction to indemnify the Buyer for covered losses it suffers resulting from a breach of the representations and warranties made by the Seller (and/or selling shareholders) in the acquisition agreement. |
| Cap (Indemnification) | A limitation on the Seller's indemnification of the Buyer by setting a maximum amount of liability of the Seller. Caps may also be set for individual or specific claims. |
| Cap (Purchase Price Adjustments) | A limitation on the post-closing purchase price adjustment (aka working capital adjustment) payable to Buyer or Seller. The PPA Cap is frequently equivalent to the general liability cap or the PPA escrow amount or may be set forth as another fixed dollar amount or tied to another provision in the acquisition agreement. |
| Capitalization | The equity ownership of the target company (e.g., number and types of securities issued and outstanding). |
| Change In Control | A merger, consolidation, or acquisition involving all or substantially all the assets of an entity. Changes in control often trigger acceleration provisions (e.g., vesting of equity compensation paid to officers or other employees or with respect to earnouts). |
| Closing Date | The date on which the transaction is consummated, i.e., the date on which the purchase price is paid, and the merger occurs. |
| Covenant | Covenants are actions that must be taken or not taken by the parties. In a merger agreement, covenants may require the parties to take actions both before and after the closing. |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Glossary (E–K)

| | |
|---|---|
| **Earnout** | Contingent consideration earned and payable after a set period of time and/or based on the level of achievement of certain milestones such as financial metrics (e.g., revenue, EBITDA, etc.) or operational metrics (e.g., regulatory approval). |
| **Escrow** | In the M&A context, a portion of the transaction consideration that is held to secure the selling shareholders' indemnification obligations to the Buyer such as a purchase price adjustment, indemnification claim, tax liability, or pending litigation. After a predetermined period of time has passed, any amount in the escrow account not claimed by the Buyer is released to the selling shareholders. |
| **Expense Fund** | A voluntary fund set aside by the shareholders from the acquisition consideration at closing for potential third-party expenses that might be incurred during the post-closing period such as costs incurred in negotiating the purchase price adjustment or defending an indemnification claim. |
| **Fiduciary Duty** | An obligation or duty to act in the best interests of another party. |
| **Fraud** | Acquisition agreements may include an express definition for "fraud" tied to a jurisdiction, such as defined under Delaware law, or using one or more elements such as actual fraud, intent to deceive, intentional fraud, intentional misrepresentation, and constructive or negligent fraud. Alternatively, an acquisition agreement may use "fraud" without including an express definition. |
| **GAAP** | Generally Accepted Accounting Principles; guidance promulgated by certain policy authorities and commonly accepted accounting practices used for consistency in reporting financial information. |
| **Holdback** | Similar to escrows, holdbacks provide security for Seller's post-closing obligations in an M&A transaction. But unlike escrows, holdbacks remain in the sole custody of the Buyer. For that reason, holdbacks may give Buyers additional leverage for post-closing disputes such as indemnification claims. After a predetermined period of time has passed, any amount of the holdback not claimed by the Buyer is released to the selling shareholders. |
| **Indemnification** | Where one party secures another against suffered losses. In the M&A context, the selling shareholders often agree to indemnify the Buyer against certain types of losses that could be suffered in connection with the transaction such as in the event of losses resulting from a breach of a representation, warranty, or covenant set forth in the acquisition agreement. |
| **Knowledge** | Acquisition agreements generally include two concepts when defining knowledge: (1) who and (2) actual versus constructive knowledge. Definitions of knowledge for a particular entity typically encompass the knowledge of officers and directors and may include additional groups related to the entity (e.g., key employees). Actual knowledge is information actually known to the person. Constructive knowledge is information that the person should know given their position or would know after investigation or due inquiry. |
| **Knowledge Qualifier** | A representation and warranty (e.g., a statement about the operations or conditions of an entity's business) can either be stated as a fact (i.e., with no knowledge qualifier) or stated as true "to the Knowledge of the Company" (i.e., with a knowledge qualifier), which would mean that the Seller is not in breach of making such representation and warranty even if such statement is not true if the Seller did not have Knowledge that such statement was not true. |



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Glossary (Le–Non)

| | |
|---|---|
| **Legal Opinion** | A legal opinion provided by Seller's counsel to Buyer that addresses the legal status of the assets being sold, legal and contractual restrictions, compliance with law and enforceability. Specialized opinions may be provided for certain patent, tax, litigation, or other specific legal matters. |
| **Legal Representation Conflict Waiver** | A provision allowing the Seller's pre-closing counsel to represent the selling shareholders post-closing in matters relating to the acquisition. |
| **Management Carveout** | A portion of deal proceeds guaranteed to the Seller's management when management would otherwise receive little or nothing for their equity ownership due to liquidation preferences. Transaction bonuses, which often differ materially from management carveouts in size and timing of adoption, are not included in our data. |
| **Management Rollover** | When an M&A transaction uses all cash consideration but allows for a subset of the selling shareholders, typically the target's management group, to exchange some or all of their equity in the target for equity in the surviving entity. |
| **Material Adverse Change (MAC)** | Typically expressly defined in an acquisition agreement, material adverse changes are substantial changes to the business, prospects, operations, results of operations, assets, liabilities or condition (financial or otherwise) of the target company or, more simply, may be tied to the definition of Material Adverse Effect (e.g., any event, development or circumstance that has had or could reasonably be expected to have a Material Adverse Effect). |
| **Material Adverse Effect (MAE)** | Typically expressly defined in an acquisition agreement, material adverse effect means any result, occurrence, fact, change, event, or effect that has a materially adverse effect on the business, assets, liabilities, capitalization, condition (financial or other), or results of operations of Seller. The definition may also include "prospects" of the Seller, which expands the definition to include planned, potential, contingent or even yet-unknown business activities. The definition may also be expanded by including forward-looking language (…any effect that has, or could reasonably be expected to have, a materially adverse effect…). The definition may be pared back with certain carveouts (e.g., changes in laws, actions required by the acquisition agreement, etc.), which carveouts may be cancelled out if such carved out occurrence had a disproportionate effect on the Seller (i.e., the adverse effect of such occurrence was substantially more significant to the Seller than to other comparable entities, such as a competitor or similar company in the same industry). |
| **Materiality Scrape** | Notwithstanding any materiality qualifiers included in a representation or warranty, for purposes of (1) determining whether a breach of such representation or warranty occurred or (2) calculating the amount of an indemnifiable loss as a result of such breach, materiality will be disregarded. A "double materiality scrape" includes both (1) and (2). |
| **Mediation** | A form of alternative dispute resolution where the parties attempt to negotiate a settlement with the assistance of a neutral third party. Unlike arbitration or litigation, the resulting agreement, or lack thereof, is wholly controlled by the parties. |
| **Non-U.S.-based Buyer** | Includes foreign companies headquartered outside of the U.S. Both public and private foreign companies are included. |



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Glossary (Nos–Sp)

| | |
|---|---|
| **No-shop/No-talk** | Seller is not permitted to initiate or engage in discussions with a competing acquirer, which gives the present acquirer exclusivity (and incentive to pursue the transaction). Certain jurisdictions have affirmed that the board of a target company may still owe a fiduciary duty to the shareholders of such target company to consider all acquisition proposals regardless of a contractual no-shop/no-talk provision to ensure maximum value to the shareholders. |
| **No Survival** | For purposes of this study, no survival or a "walk-away" deal means the Seller's general representations and warranties do not survive closing, however, Sellers may still be liable for carved-out matters, such as fundamental reps and warranties, special indemnities, etc. |
| **Option** | A type of security where the holder may elect to purchase equity (e.g., shares of capital stock) at a certain price often used as a form of compensation for officers or employees of an entity and subject to a vesting schedule. Holders of options that are in-the-money (where the current value of the underlying equity is more than the price payable pursuant to the option) may receive consideration in an acquisition transaction in exchange for their options, sometimes even participating in the PPA and escrow provisions alongside the holders of capital stock (e.g., "contribution"). An acquisition may trigger change in control provisions, accelerating the vesting schedule of the options. A Buyer may also elect to assume options, whereby the option would permit the holder to purchase equity in the Buyer after closing. |
| **Private Buyer (U.S.)** | Non-public companies headquartered in the U.S. Also includes companies whose stock is traded on the OTCBB or Pink Sheets and potentially the portfolio companies of private equity firms (i.e., P.E-backed). |
| **Public Buyer (U.S.)** | Acquiring companies listed on U.S. public stock exchanges (e.g., NYSE or NASDAQ). |
| **Purchase Price Adjustment (PPA)** | A common deal feature where the transaction consideration is adjusted shortly after closing in accordance with a specified financial metric given such metrics are generally estimated at the time of closing and more accurately calculable after a certain amount of time after closing. While there are a number of metrics used to determine the adjustment, the most common is some variation of a net working capital formula. The adjustment can be in favor of either the Buyer or selling shareholders. |
| **Representations and Warranties Insurance (RWI)** | A commercial insurance policy purchased from a third-party insurance provider that provides coverage for breaches of representations and warranties, often subject to a deductible (i.e., retention amount) and express coverage carveouts. RWI is most often purchased by the Buyer with the premium considered a transaction expense. The retention amount of the RWI policy often correlates to the size of the indemnification escrow/holdback. |
| **Sandbagging** | Having knowledge of a breach of a representation, warranty, or covenant of the other party under the acquisition agreement and continuing with the consummation of the transaction nonetheless and potentially seeking indemnification for any losses that may result from such breach post-closing. |
| **Signing date** | The date on which the merger agreement is signed by the principal parties. Closing typically, but not always, occurs on a later date. |
| **Special Escrows** | For purposes of this study, special escrows are deal escrows or holdbacks other than the general indemnification escrow such as a separate escrow for the PPA, specific indemnities, known litigation liabilities, intellectual property liabilities, tax liabilities, key employee retention issues, earnouts, regulatory liabilities, and data privacy liabilities. |



©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 


# Glossary (Su–U)

| | |
|---|---|
| **Survival** | The time period after closing during which the Buyer may make a claim against the Seller or selling shareholders for breach of their representations, warranties, and covenants. The time period is usually shorter than the applicable statute of limitations. |
| **Termination Fee** | A fee payable in the event the acquisition transaction is not consummated, generally included to cover transaction expenses. |
| **Transaction Bonus** | Compensation payments to officers and/or key employees in connection with the acquisition transaction often for purposes of retention. |
| **Transaction Expenses** | Typically expressly defined in the acquisition agreement, transaction expenses generally include expenses incurred by the Seller and Buyer to consummate the transaction and may include (or exclude) the fees of brokers, advisors, counsel and third-party vendors (e.g., escrow agent), costs associated with regulatory approvals or obtaining certain consents, transaction bonuses, change in control payments and severance, and/or other expenses incurred in connection with the negotiation, preparation, review, execution, delivery, or performance of the acquisition agreement or consummation of the transaction. |
| **Transaction Value** | The enterprise value to be paid by the Buyer according to the acquisition agreement. For purposes of this study, transaction value does not include contingent consideration (e.g., earnouts) or adjustments to the purchase price. |
| **U.S. Private Equity Buyer** | Buyer that acquires a target as an investment rather than for the purpose of expanding its own business or for other strategic purposes. |


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

SRS ACQUIOM MARKETSTANDARD™

# The Industry's Most Powerful Deal Analytics Tool




## 01

### The Most Comprehensive View of Deal-term Outcomes

- More than a decade of private-target M&A deal terms in a simple, powerful, visual, interactive online platform.

## 02

### Determine "What's Market"

- Compare market data to your deal terms.
- Filter data to more closely resemble the deal you're negotiating.
- Draw information from more than 4,500 deals—with more added quarterly.

## 03

### Customize Your View of the Data

- You determine what is relevant to your deal to negotiate with real-time knowledge.
- Dynamically filter, sort, and explore more than 150 attributes with five different filters.

► Visit srsacquiom.com/marketstandard/

SRS ACQUIOM

©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 

# Contact Us

303.648.4085
srsacquiom.com

MEDIA INQUIRIES
media@srsacquiom.com

STUDY INQUIRIES
dts@srsacquiom.com

PROSPECTIVE CLIENTS
sales@srsacquiom.com

EXISTING CLIENTS
support@srsacquiom.com

SRSACQUIOM

# Additional Resources

- 2025 M&A Working Capital PPA Study
  https://www.srsacquiom.com/our-insights/2025-working-capital-purchase-price-adjustment-study/
- 2024 SRS Acquiom Claims Insight Report:
  https://www.srsacquiom.com/our-insights/ma-claims-insights-report-earnout-indemnification-data/
- 2023 SRS Acquiom Life Sciences M&A Study:
  https://www.srsacquiom.com/resources/life-sciences-deal-terms/
- SRS Acquiom MarketStandard®:
  https://www.srsacquiom.com/marketstandard/

---

Please note that we cannot provide data that can be used to ascertain confidential information about deals or clients.

The information herein may not be stripped of any copyright or trademark information or copied, published or used, in whole or in part, for any other purpose than as expressly authorized by SRS Acquiom. In preparing this study, we have relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources or that was provided to us by or on behalf of our clients or that was otherwise reviewed by us. The terms of the agreements surveyed for this Study vary widely and are subject to competing interpretations; therefore, the conclusions presented in this Study are subject to important qualifications that are not expressly articulated. SRS Acquiom makes no representations as to, and no party shall be entitled to rely upon, the legal, regulatory, or tax implications of the matters referred to herein, and neither SRS Acquiom nor any of its directors, officers, employees, or agents shall incur any responsibility or liability whatsoever to any party in respect of the contents of this study or any matters referred to in, or discussed as a result of, this document.


©2025 SRS Acquiom Inc. All rights reserved. Proprietary & Confidential. 


SRS ACQUIOM®
ELEVATE
YOUR GAIN™